{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:31:58Z","timestamp":1762432318264,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.leukres.2023.107037","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T10:45:46Z","timestamp":1676112346000},"page":"107037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-6644","authenticated-orcid":false,"given":"Michael","family":"Slade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5023","authenticated-orcid":false,"given":"Mark","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-9149","authenticated-orcid":false,"given":"Sarah","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary D.","family":"Crees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-1715","authenticated-orcid":false,"given":"Keith","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2023.107037_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2023.107037_bib2","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2023.107037_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.16793","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2023.107037_bib4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2023.107037_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transpl."},{"issue":"7","key":"10.1016\/j.leukres.2023.107037_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/bmt.2016.43","article-title":"Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the singapore multiple myeloma working group","volume":"51","author":"Ong","year":"2016","journal-title":"Bone Marrow Transpl."},{"issue":"4","key":"10.1016\/j.leukres.2023.107037_bib7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2023.107037_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bmt.2014.237","article-title":"Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents","volume":"50","author":"Jimenez-Zepeda","year":"2015","journal-title":"Bone Marrow Transpl."},{"issue":"23","key":"10.1016\/j.leukres.2023.107037_bib9","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2023.107037_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.leukres.2023.107037_bib11","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1158\/1078-0432.CCR-21-0134","article-title":"Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients","volume":"27","author":"Zaccaria","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.leukres.2023.107037_bib12","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"FORTE: carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alo","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.leukres.2023.107037_bib13","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"D\u2019Agostino","year":"2020","journal-title":"Clin. Cancer Res"},{"volume":"Vol 24","year":"2018","author":"Ledergor","key":"10.1016\/j.leukres.2023.107037_bib14"},{"issue":"5","key":"10.1016\/j.leukres.2023.107037_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clml.2019.01.003","article-title":"Next generation sequencing-based validation of the revised international staging system for multiple myeloma: an analysis of the MMRF CoMMpass study","volume":"19","author":"Goldsmith","year":"2019","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2023.107037_bib16","first-page":"1","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.leukres.2023.107037_bib17","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107037_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","author":"D\u2019Agostino","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2023.107037_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.374.374","article-title":"A comparison of clinical FISH and sequencing based FISH estimates in multiple myeloma: an MMRF commpass analysis","volume":"128","author":"Miller","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2023.107037_bib20","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2023.107037_bib21","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107037_bib22","unstructured":"R.T. RStudio: Integrated Development Environment for R. RStudio P, ed. Boston, MA."},{"issue":"3","key":"10.1016\/j.leukres.2023.107037_bib25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2023.107037_bib26","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2023.107037_bib27","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2023.107037_bib28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.leukres.2023.107037_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.leukres.2023.107037_bib30","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107037_bib31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2023.107037_bib32","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107037_bib33","first-page":"1","article-title":"Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile","author":"Hofste","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107037_bib34","doi-asserted-by":"crossref","unstructured":"Binder M., Szalat R., Fulcinit M., et al. High-risk multiple myeloma due to extramedullary disease- like gene expression induced by bone marrow stromal cells. In: International Myeloma Society 19th Annual Meeting and Exposition. Los Angeles, California; 2022:14.","DOI":"10.1016\/S2152-2650(22)00294-4"},{"issue":"24","key":"10.1016\/j.leukres.2023.107037_bib35","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87\/NMSG-18 trial","volume":"4","author":"Kuiper","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107037_bib36","first-page":"1","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","author":"Bertamini","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262300022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262300022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:04Z","timestamp":1758934984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262300022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":34,"alternative-id":["S014521262300022X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107037","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107037"}}